Chapter 9 276 in a recent meta-analysis attempting to summarize long COVID prevalence[52]. Among nine studies with a mix of hospitalised and non-hospitalised individuals with SARS-CoV-2 infection, exclusively enrolling individuals living in Asia, Europe or the Americas, a pooled prevalence of 0.32 (95% CI: 0.14–0.57) of long COVID was found. Extremely high heterogeneity (I2 = 100%) was noted between the included studies due to different definitions of long COVID, time since infection of symptom assessment, and selections of symptoms measured. Figure 9.1. Proportions of RECoVERED cohort participants (Amsterdam, the Netherlands) with long COVID over time, according to four definitions with different selections of symptoms Data presented above are from month 3 onwards, in line with the common definitions of long COVID. Subsequent selection of these symptoms was made according to the following criteria: * Any of the 20 symptoms included in the questionnaire ** COVID-19 symptoms, including only those symptoms with a reported start date within the first month of overall COVID-19 onset *** Counting only the four most commonly-reported long COVID symptoms in our cohort: fatigue, dyspnoea, loss of smell/taste and myalgia **** Counting only the four most commonly-reported long COVID symptoms in our cohort if they had persisted since illness onset (i.e., individuals with a later relapse in any of these four symptoms were no longer included in the numerator)
RkJQdWJsaXNoZXIy MTk4NDMw